Kornimate/medical-research-clean huggingface dataset:
elucidation of sensory characteristics and food preferences in the elderly

Conditions: Malnutrition

Summary: malnutrition is a frequent problem in persons older than 65 years: the prevalence of malnutrition can reach 25 to 29% in persons living at home who require help, figures vary between 19 and 38% for those living in institutions, and finally, the prevalence of malnutrition in hospitalized elderly patients can reach 30 to 90%. a few studies have attempted to explain modifications in attitudes, behaviour, the frequency of meals or nutritional status in the elderly by a fall in chemosensory sensitivity the aim of this project is to test the hypothesis that perhaps it is not as much the capacity to perceive a smell or a taste that affects eating behaviour in the elderly as their ability to distinguish between smells or tastes on the one hand (perceptual processing), and their ability to correctly interpret a chemosensory signal on the other (cognitive processing).


Eligibility criteria:
inclusion criteria: * persons older than 65 years. * persons with diabetes, heart disease or hypertension stabilized by a treatment. * persons cognitively able to carry out the tests and fill in the questionnaires (folstein test between 22 and 30). exclusion criteria: * any person suffering from an acute disease at the time of the test. * any person presenting any allergy whatsoever (food, mites, pollen...). * any person suffering from asthma or severe respiratory disorders (lung cancer, tracheotomy...). * any person presenting anosmia (total loss of olfaction) from birth or following physical trauma (head injury) or due to disease (severe rhinitis). * persons with diabetes, heart disease or hypertension not stabilized by treatment. * any person presenting life expectancy of less than 6 months.

Keywords: elderly
thiamine as adjunctive therapy for diabetic ketoacidosis

Conditions: Diabetic Ketoacidosis

Summary: this is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. the investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (icu) and hospital stay or decreases hospital resource utilization.

thiamine (vitamin b1) is a water-soluble vitamin that plays a key role in aerobic glucose metabolism. thiamine is a cofactor of pyruvate dehydrogenase (pdh), an enzyme that must be activated for entry into the krebs cycle for aerobic metabolism. pdh activity is reduced in thiamine deficient states, resulting in a shift in pyruvate metabolism to the anaerobic pathway. this leads to increased lactate production and acidosis. thiamine loss in the urine, with consequent thiamine deficiency, is not uncommon in diabetes. the investigators' preliminary studies have found that thiamine deficiency in occurs in as many as 39% of patients with dka, and that thiamine levels are inversely associated with lactate and acidosis. the investigator hypothesizes that treating dka patients with intravenous thiamine will lead to faster resolution of acidosis and improved aerobic metabolism. the investigator's secondary hypothesis is that thiamine treatment will shorten stays in the icu and hospital and lead to utilization of fewer hospital resources. in this randomized, double-blind, placebo-controlled trial, patients admitted to the hospital with dka who are enrolled in the study will be randomized to either intravenous thiamine (200mg in 0.9% saline) twice daily for two days or an identical volume of 0.9% saline on the same schedule. the investigator's primary outcome is change in bicarbonate over the 24 hours following enrollment, with measurements at 0, 6, 12, 18, 24 hours, using a linear mixed-effects model. secondarily, patients will be stratified by type i and type ii dm. additionally, a pre-planned sub-analysis of thiamine deficient subjects will be performed.

Eligibility criteria:
inclusion criteria: * bicarbonate ≤15 meq/l * anion gap \> 12 meq/l * blood ph≤ 7.24 (if already obtained by clinical team) * urine ketones (qualitative) or serum ketones (β-hydroxybutyric acid) \> 3 mmol/l * enrollment within 6 hours of presentation exclusion criteria: * current thiamine supplementation ≥ 6 milligrams per day (i.e., more than a multivitamin) * competing causes of severe acidosis including seizure, carbon monoxide poisoning, cyanide toxicity, cardiac arrest, liver dysfunction (specifically defined as known cirrhosis) * known allergy to thiamine * competing indication for thiamine administration as judged by the clinical team (e.g., significant alcohol use) * research-protected populations (pregnant women and prisoners) * patient enrolled previously in same study * code status of do not resuscitate/do not intubate (dnr/dni) or comfort measures only (cmo)

Keywords: diabetic ketoacidosis dka thiamine acidosis oxygen consumption lactate
the effect of cannabis in pancreatic cancer

Conditions: Neoplasms Pancreatic; Cachexia; Cancer; Cannabis; Appetite Loss; Palliative Medicine; Morbidity; Mortality

Summary: cannabinoids are known to increase appetite, but thc components have psychogenic properties too. cbd is the main component in the plant, and have only minimal psychogenic effects. the aim was to test the appetite stimulating effects of cbd in patients with pancreatic cancer in palliative treatment.

randomization of consecutive patients who wanted to participate to a daily dose of cbd or not as a supplement to the standard treatment.

Eligibility criteria:
inclusion criteria: * adult, palliative pancreatic cancer diagnosis, weight loss \> 5%, understand and read danish. exclusion criteria: * regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy \< 6 months
correlation between femoral head and cup size and postoperative pain in total hip arthroplasty

Conditions: Femoral Head Size; Cup Size THP; Postoperatie Groin Pain

Summary: we want to investigate the correlation between the native femoral head and the implanted cup in total hip arthroplasty. as second parameter to investigate we believe an oversized cup will cause groin pain. we want to find a cutoff value to predict groin pain after cup implementation in tha.


Eligibility criteria:
inclusion criteria: * all primary tha exclusion criteria: * ddh-lcp * acetabulum/femoral neck fracture
identification of depressive and anxiety symptoms among a sample of emergency department patients using artificial intelligence (ai) technology

Conditions: Artificial Intelligence (AI)

Summary: behavioral health problems, such as depression and anxiety, are common yet often are not identified by emergency department doctors and nurses. these mental health conditions can be due to medical issues or can worsen medical problems. one way investigators hope to do a better job of learning about mental health is by training artificial intelligence (ai) software to detect anxiety and depression by analyzing facial expression and tone of voice. participants are invited to participate in a study which may help improve emergency department care. an audio and video recording of the participant's responses to some simple, non-psychological questions will be analyzed by a computer to determine whether investigators can assess mood and anxiety by analyzing speech and visual patterns. the audio and video will not be listened to nor watched by study personnel, only analyzed by a computer. the investigator's hope is that it will help others in the future by aiding in the assessment of psychological state. this study is being conducted at cmc ed only.


Eligibility criteria:
inclusion criteria: * adult patients (age 18 and over) who presents to the uhcmc ed voluntarily with no obvious psychological disturbance by self-report or nurse/provider initial assessment * english-speaking * patients with non-emergent concerns of emergency severity index (esi) level 3, 4, or 5 exclusion criteria: * prisoners * patients who are deemed to be critically ill (including life or limb threatening illness) or unable to consent * non-english speaking

Keywords: depression anxiety emergency department
hba1c in intracytoplasmic sperm injection

Conditions: Infertility

Summary: icsi has increased nowadays for treating cases of longstanding infertility . hba1c has an important value in evaluating glucose level in blood

- the level of hba1c in blood denotesnthe glycemic control over the past 3 months . its regulation is very important in human reproductive life

Eligibility criteria:
inclusion criteria: * females with infertility from 20 to 42 years old exclusion criteria: * females with age below 20 or above 42 years
three-dimensional ultrasonography versus hysteroscopy in evaluation of uterine cavity in infertile women

Conditions: Female Infertility

Summary: hysteroscopy has now become a gold-standard technique carried out for uterine cavity assessment in infertile women. apart from direct visualizing of the endometrium by the naked eye, pathologies missed by other modalities of investigation can be picked up and managed appropriately. unfortunately, the procedure itself is not free from complications e.g. perforation, cervical laceration, bleeding, limited access in cases of cervical stenosis and considered as an invasive procedure. two-dimensional transvaginal ultrasonography (2d-tvs)and three-dimensional tvs (3d-tvs) are non-invasive methods for evaluating the uterine cavity. the3d-tvs is superior to 2d-tvs in identifying uterine cavity abnormalities due to its ability to obtain a view of three different planes of the uterus, which could be used to locate the position of intracavitary pathology. reports vary regarding the diagnostic accuracy of 3d-tvs that was reported to have 41.3-81.5% sensitivity and 94.6-98.7% specificity. so it became clear that 3d-tvs is a non-invasive and safe diagnostic tool for evaluation of the uterine cavity abnormalities but its sensitivity, specificity and accuracy still a matter of debate and warrants more evaluation.


Eligibility criteria:
inclusion criteria: * infertile women (primary or secondary) * age between 18 and 40 years. exclusion criteria: * age\<18 years and˃ 40 years. * pelvic inflammatory disease. * .active uterine bleeding
selective digestive decontamination in carriers of carbapenem-resistant klebsiella pneumoniae

Conditions: Carriage of Carbapemen-resistant Klebsialle Pneumoniae

Summary: there is an urgent need to control our current national outbreak of carbapenem-resistant klebsiella pneumoniae (crkp). the purpose of this study is to eradicate crkp gastrointestinal carriage using selective digestive decontamination (sdd); with buccal and oral gentamicin and polymyxin e administration. this will reduce infections and hopefully mortality caused by crkp.


Eligibility criteria:
inclusion criteria: * hospitalized men and women with a positive rectal swab for crkp * age 18 years or older exclusion criteria: * age less than 18 years * pregnant women, lactating women * a known allergy to the study drugs
the effects of inhaled iloprost on congenital heart disease with eisenmenger syndrome

Conditions: Eisenmenger's Syndrome

Summary: identification of the pathophysiology associated with eisenmenger's syndrome has led to the evaluation of targeted therapies. iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with eisenmenger's syndrome. the purpose of our study is to assess the effects of inhaled iloprost on patients with eisenmenger's syndrome.


Eligibility criteria:
inclusion criteria: * patients with eisenmenger's syndrome diagnosed by right side cardiac catheterization exclusion criteria:

Keywords: iloprost, eisenmenger's syndrome
gemcitabine and carboplatin for elderly patient with lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: a comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly gemcitabine in elder patients (\> 75) with previously untreated advanced non-small cell lung cancer. primary objective is to determine the objective response rate (cr+pr by recist criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (\> 76 years) who have received no prior treatment for non-small lung cancer. as secondary objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin combination chemotherapy, progression-free survival and overall survival will be evaluated in both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly single gemcitabine. the study hypothesis is that biweekly combination chemotherapy of gemcitabine plus carboplatin may improve the efficacy.


Eligibility criteria:
inclusion criteria: * diagnosis of histologically confirmed stage iiib or iv non-small cell lung cancer * good performance status (ecog 0-1) * no previous treatment * age 76 years and older * adequate bone marrow, liver and renal functions * no pregnant * measurable disease, defined as at least one lesion whose longest diameter can be accurately measured as \>=1.0 cm by spiral ct scan * provided written informed consent exclusion criteria: * severe complications or a concomitant malignancy * prior and other concurrent radiotherapy, chemotherapy, immunotherapy, egfr tyrosine kinase inhibitors * interstitial pneumonia or lung fibrosis * contraindicated gemcitabine or carboplatin * inappropriate patients for entry to this study, judged by the physicians

Keywords: elder patients non-small cell lung cancer previously untreated advanced
comparison across treatment conditions to reduce smokeless tobacco use

Conditions: Tobacco Use Disorder

Summary: smokeless tobacco (st), which includes both chewing tobacco and snuff, has health risks associated with its use. while treatment programs that focus on stopping tobacco use may be effective, past research has shown that interventions that specifically focus on reducing tobacco use may be equally effective and may motivate individuals to eventually quit using tobacco. this study will compare the effectiveness of a st reduction treatment program versus a usual tobacco cessation treatment program (immediate cessation) for reducing tobacco use in st users.

individuals who use st are at increased risk for cancer or dying from cardiovascular disease. other long-term effects include tooth abrasion, gum recession, and loss of bone in the jaw. many individuals who use st recognize the health risks associated with st, but either do not want to quit or feel that it is impossible to quit. for these individuals, tobacco reduction may be an important transitional goal, either prior to quitting or as a treatment endpoint. by participating in a tobacco reduction program, these individuals may be motivated to eventually stop using tobacco altogether. the purpose of this study is to compare a st reduction treatment program versus a standard tobacco cessation treatment program (immediate cessation) for reducing tobacco use in st users. this study will enroll regular users of st. participants will be randomly assigned to either a tobacco reduction program or to usual care, a standard tobacco cessation program during the first telephone contact. at the first clinic visit, participants assigned to the tobacco reduction group will replace their usual brand of st with one of two options: an st brand with less nicotine or nicotine lozenge. participants will be encouraged to reduce their nicotine intake by at least 50% the first two weeks and encouraged to further reduce their nicotine intake in the following 4 weeks. participants assigned to the usual care group will be advised to quit and will be asked to set a quit date within two weeks. telephone counseling, ideas on methods for sustaining cessation, and a self-help manual will also be provided along with a 2 week supply of nicotine patches. study visits will occur at 2, 4, 8, 12, 26, and 32 (for reduction group) weeks. outcome assessments will include vital signs, physiological measures related to tobacco use, levels of nicotine reduction, tobacco use status, and measures of motivation and self-efficacy to quit.

Eligibility criteria:
inclusion criteria: * no interest in stopping st use within 90 days of study entry * daily use of st in the 6 months prior to study entry exclusion criteria: * current use of tobacco or nicotine products, other than st * current unstable medical and mental health conditions * use of any medication that may affect tobacco use or be affected by a reduction in tobacco use * pregnant or breastfeeding

Keywords: nicotine dependence tobacco dependence
long-term outcomes of pregnant women with pah

Conditions: Pulmonary Arterial Hypertension

Summary: the investigators intend to explore the characteristics and outcomes of pregnant women with pah during different pregnancies and to provide applicable evidence for clinical practice.

pulmonary arterial hypertension (pah) is a fatal disease with progressive vascular resistance that leads to the loss of right heart function. avoiding pregnancy is essential for pah women. in recent years, maternal mortality in pregnant women with pah has decreased mostly due to emerging advanced therapies for pah and the progress in high-risk pregnancy management. nevertheless, the maternal death rate in parturients with pah remains high; therefore, contraception is still recommended for women diagnosed with pah. however, some women develop this condition during pregnancy. with the two-child policy, families in china are allowed to have a second child. as a result, the number of pah diagnoses during pregnancy may increase with the general increase in the number of pregnant women. additionally, some patients develop pah only during their second pregnancy. in order to investigate the incidence and clinical characteristics of pregnant women diagnosed with pah during different pregnancies, this observational study aimed to analyze perinatal and pregnancy clinical data, to compare the perinatal status and maternal and infant outcomes of the first and second pregnancies complicated with pah, establishing a clinical basis for the prenatal consultation, diagnosis, and treatment of pregnant women with pah.

Eligibility criteria:
inclusion criteria: pah was screened by doppler echocardiography first. echocardiographic criteria for the diagnosis of pah included tricuspid regurgitation velocity \>2.8 m/sec, with extra more than one additional echocardiographic sign exclusion criteria: cases of ph diagnosed before pregnancy, secondary to chronic lung disease, and left heart disease, as well as right ventricular outflow tract obstruction and congenital pulmonary stenosis.
a single and multiple ascending doses study to evaluate the safety, tolerability and pharmacokinetics of rbd7022

Conditions: Hyperlipemia

Summary: this is a randomized, single blind, placebo controlled, single center phase i study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously administered rbd7022 in participants with normal or elevated ldl-c cholesterol. the study will be performed in 2 phases: single ascending dose (sad) phase and multiple ascending doses (mad) phase in participants. the decision to escalate to subsequent dose levels will be made by the src based on the review of all available safety information in each cohort.


Eligibility criteria:
inclusion criteria: * male and female subjects, aged 18 to 65 years, inclusive * body mass index between 17 and 28 kg/m2 , inclusive * ldl-c normal or elevated at screening and baseline. * willing to comply with protocol required visit schedule and visit requirements and provide written informed consent. * the clinical laboratory examination of the subjects was within the normal range, or abnormal but had no clinical significance as judged by the investigators, and did not affect the study results; * vital signs, physical examination, ecg, ultrasound showed normal or abnormal but no clinically significant as determined by the investigator. exclusion criteria: * with a clear history of primary diseases of major organs, the subject is not suitable to participate in this study considered by the investigator; * diagnosis of diabetes mellitus; * pregnant or breastfeeding women; * any conditions which, in the opinion of the investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
effectiveness, safety and use of nivolumab administered during the french temporary authorization for use in patients with advanced melanoma

Conditions: Melanoma

Summary: this study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the atu setting.


Eligibility criteria:
inclusion criteria: * patients included in ric-mel database: * diagnosed with melanoma and cared for in the participating sites * patients who have been given appropriate information about ric-mel database aims and who have provided their written consent for data collection and processing before any data collection is carried out * patients included in french nivolumab atu program exclusion criteria: • patients included in ric-mel database having initiated nivolumab before 12-sep-2014 or after 31-aug-2015, or in the context of a clinical trial other protocol defined inclusion/exclusion criteria could apply